MedWatch

Genmab's chief development officer sells shares in US

On Tuesday, a transaction involving Genmab shares worth USD 390,771 took place in the US.

Photo: Tuala Hjarnø / Genmab / Pr

Executive Vice President & Chief Development Officer at Genmab Judith Klimovsky sold 900 American Depository Shares, ADSs, at a price per share of USD 434.2 on Tuesday, the company writes in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs